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OBJECTIVE
There is no information about the role of nonalcoholic fatty liver disease (NAFLD)
in predicting the development of chronic kidney disease (CKD) in type 1 diabetes.
RESEARCH DESIGN AND METHODS
We studied 261 type 1 diabetic adults with preserved kidney function and with no
macroalbuminuria at baseline, who were followed for a mean period of 5.2 years
for the occurrence of incident CKD (deﬁned as estimated glomerular ﬁltration rate
[eGFR] <60mL/min/1.73 m2 and/or macroalbuminuria). NAFLD was diagnosed by
ultrasonography.
RESULTS
At baseline, patients had amean eGFR of 926 23mL/min/1.73m2; 234 (89.7%) of
them had normoalbuminuria and 27 (10.3%) microalbuminuria. NAFLD was pres-
ent in 131 (50.2%) patients. During follow-up, 61 subjects developed incident CKD.
NAFLD was associated with an increased risk of incident CKD (hazard ratio [HR]
2.85 [95% CI 1.59–5.10]; P < 0.001). Adjustments for age, sex, duration of diabetes,
hypertension, A1C, and baseline eGFR did not appreciably attenuate this associ-
ation (adjusted HR 2.03 [1.10–3.77], P < 0.01). Results remained unchanged after
excluding those who had microalbuminuria at baseline (adjusted HR 1.85 [1.03–
3.27]; P < 0.05). Addition of NAFLD to traditional risk factors for CKD signiﬁcantly
improved the discriminatory capability of the regression models for predicting
CKD (e.g., with NAFLD c statistic 0.79 [95% CI 0.73–0.86] vs. 0.76 [0.71–0.84]
without NAFLD, P = 0.002).
CONCLUSIONS
This is the ﬁrst study to demonstrate that NAFLD is strongly associated with an
increased incidence of CKD. Measurement of NAFLD improves risk prediction for
CKD, independently of traditional cardio-renal risk factors, in patients with type 1
diabetes.
Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions worldwide
(1). Up to 30% of adults in the U.S. and Europe have NAFLD, and the prevalence of this
disease is much higher in people with diabetes (1,2). Indeed, the prevalence of NAFLD
on ultrasonography ranges from;50 to 70% in patientswith type 2 diabetes (3–5) and
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;40 to 50% in patients with type 1 dia-
betes (6,7). Notably, patients with diabe-
tes and NAFLD are also more likely to
develop more advanced forms of NAFLD
that may result in end-stage liver disease
(8). However, accumulating evidence in-
dicates that NAFLD is associated not only
with liver-relatedmorbidity andmortality
but also with an increased risk of devel-
oping cardiovascular disease (CVD) and
other serious extrahepatic complications
(8–10).
In recent years, the possible link be-
tween NAFLD and chronic kidney disease
(CKD) has also attracted considerable sci-
entiﬁc interest (11). CKD is now recog-
nized as a common condition that
markedly increases the risk of end-stage
renal disease (ESRD), CVD, and other im-
portant comorbidities. The number of
patients with ESRD is increasing and
represents a major public health problem
worldwide (12–14). Because kidney dis-
ease often progresses to ESRD with its
attendant complications, the identiﬁca-
tion of precursors and risk factors for
CKD is essential, with the belief that inter-
ventions might prevent or delay progres-
sion to ESRD.
Increasing evidence indicates that
NAFLD is strongly associated with an in-
creased risk of CKD in people with and
without diabetes (11). Indeed, we have
previously shown that NAFLD is associ-
ated with an increased prevalence of
CKD in patients with both type 1 and
type 2 diabetes (15–17), and that NAFLD
independently predicts the development
of incident CKD in patients with type 2
diabetes (18). However, many of the risk
factors for CKD are different in patients
with type 1 and type 2 diabetes, and to
date, it is uncertain whether NAFLD is an
independent risk factor for incident CKD
in type 1 diabetes or whether measure-
ment of NAFLD improves risk prediction
for CKD, taking account of traditional risk
factors for CKD.
Therefore, the aim of the current study
was to investigate 1) whether NAFLD is
associated with an increased incidence
of CKD and 2) whether measurement of
NAFLD improves risk prediction for CKD,
adjusting for traditional risk factors, in
type 1 diabetic patients.
RESEARCH DESIGN AND METHODS
Patients
Using a retrospective, longitudinal co-
hort study design, we have initially
identiﬁed from our electronic database
all Caucasian type 1 diabetic outpatients
with preserved kidney function (i.e., es-
timated glomerular ﬁltration rate
[eGFR] $60 mL/min/1.73 m2) and
with no macroalbuminuria (n = 563),
who regularly attended our adult dia-
betes clinic between 1999 and 2001.
Type 1 diabetes was diagnosed by the
typical presentation of disease, the
absolute dependence on insulin treat-
ment for survival, the presence of
undetectable fasting C-peptide concen-
trations, and the presence of anti–islet
cell autoantibodies.
We subsequently excluded from anal-
ysis 1) patients for whom a liver ultra-
sound examination was not available
(n = 204), 2) those with a documented
history of cancer, cirrhosis, myocardial
infarction, angina, and coronary revas-
cularization procedures (n = 11), and 3)
those with secondary causes of chronic
liver disease, such as excessive alcohol
consumption (i.e., .30 g/day for men
and .20 g/day for women, respec-
tively), viral hepatitis, and drug-induced
liver disease (n = 87).
Overall, 261 type 1 diabetic out-
patients were included in the ﬁnal anal-
ysis and were tested for the development
of incident CKD during the follow-up pe-
riod (through 31 May 2013). No signiﬁ-
cant differences were found in main
demographic and laboratory data, includ-
ing eGFR, between patients who did and
did not have a liver ultrasound examina-
tion (data not shown).
All participants were periodically seen
(every 3–6 months) for routine medical
examinations of glycemic control and
chronic complications of diabetes. No
participants were lost to follow-up.
The local ethics committee approved
the study protocol. The informed con-
sent requirement for this study was ex-
empted by the ethics committee
because researchers only accessed
retrospectively a de-identiﬁed database
for analysis purposes.
Clinical and Laboratory Data
BMI was calculated by dividing weight in
kilograms by height in meters squared.
Waist circumference was measured at
the level of the umbilicus. Blood pres-
sure was measured in duplicate with a
standard mercury manometer. Informa-
tion on smoking, alcohol consumption,
and use of medications was obtained
from all participants by a validated ques-
tionnaire (15,16). In particular, alcohol
consumption was assessed on the basis
of the self-reported number of drinks
consumed per day. The following
amounts of alcoholic beverages were
considered one drink: 330mL beer (con-
taining;5% alcohol), 150mL wine (con-
taining;12% alcohol), and 40mL strong
alcohol (containing ;50% alcohol). By
study design, most patients included
in this analysis were abstainers (n =
208; 79.7%) or drank only minimally (n =
53; 23 women drank ,20 g and 30
men drank ,30 g of alcohol per day,
respectively).
Venous blood was drawn in the morn-
ing after an overnight fast. Serum liver
enzymes, lipids, creatinine (measured
using a Jaffe´ rate-blanked and compen-
satedassay), andother biochemical blood
measurements were determined by stan-
dard laboratory procedure (DAX 96;
Bayer Diagnostics, Milan, Italy). Normal
ranges for serum aminotransferase levels
in our laboratory were 10–40 units/L for
bothmen andwomen. Normal ranges for
serum g-glutamyltransferase (GGT) levels
were 5–55 units/L for women and 5–75
units/L for men, respectively. LDL choles-
terol was calculated by the Friedewald
equation. A1C was measured by a high-
performance liquid chromatography ana-
lyzer (HA-8140; Menarini Diagnostics,
Florence, Italy); the upper limit of normal
for our laboratory was 5.6%.
At baseline, eGFR was estimated in all
participants from the four-variable
Modiﬁcation of Diet in Renal Disease
(MDRD) study equation (19) and from
the Chronic Kidney Disease Epidemiol-
ogy Collaboration (CKD-EPI) equation
(20). Urinary albumin excretion was also
measured from an early morning urine
sample as the albumin-to-creatinine ratio
(ACR) by an immunonephelometric
method; microalbuminuria and macro-
albuminuria were deﬁned as ACR .2.5
and .30 mg/mmol for men and ACR
.3.5 and .30 mg/mmol for women,
respectively (21).
For this study, the development of in-
cident CKDwas deﬁned as occurrence of
eGFR,60mL/min/1.73 m2 and/or mac-
roalbuminuria (21). Both of these out-
come measures were conﬁrmed in all
participants in a least two consecutive
occasions (within 3–6 months after the
ﬁrst examination).
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Since waist circumference was avail-
able only in a few participants (n = 102),
metabolic syndrome was diagnosed by a
modiﬁed Adult Treatment Panel III deﬁni-
tion that used BMI instead of waist cir-
cumference. In accordance with this
deﬁnition (22), a person with type 1 di-
abetes was classiﬁed as having the meta-
bolic syndrome if he/she had at least two
of the following components: 1) BMI
.28.5 kg/m2 in men or .26.5 kg/m2 in
women; 2) triglycerides$1.7 mmol/L; 3)
HDL cholesterol ,1.0 mmol/L in men
and ,1.29 mmol/L in women, or lipid-
lowering treatment; and 4) blood pres-
sure$130/85mmHg or antihypertensive
treatment.
At baseline, hepatic ultrasonography
was performed (within ;1 month after
that blood measurements were taken)
at our institution by two experienced
radiologists who were blinded to the
patient characteristics. Hepatic steato-
sis was diagnosed on the basis of char-
acteristic ultrasonographic features,
i.e., evidence of diffuse hyperechoge-
nicity of the liver relative to the kidneys,
ultrasound beam attenuation, and poor
visualization of intrahepatic vessel bor-
ders and diaphragm (23). It is known
that ultrasonography has good sensitiv-
ity and speciﬁcity for detecting moder-
ate and severe hepatic steatosis (;90–
95%), but its sensitivity is reduced when
the hepatic fat inﬁltration upon liver bi-
opsy is,30% (23). The intra- and inter-
observer variabilities for the ultrasound
diagnosis of hepatic steatosis were
within 5%.
Statistical Analysis
Data are expressed as means 6 SD,
medians (interquartile ranges), or pro-
portions. Skewed variables (diabetes
duration, liver enzymes, triglycerides,
eGFR, urinary ACR, and daily insulin
dose) were logarithmically transformed
to improve normality prior to analysis.
The unpaired Student t test and the x2
test with Yates correction for continuity
(for categorical variables) were used to
compare baseline characteristics of pa-
tients between those who developed
CKD at follow-up and those who did
not (Table 1) or between those with
and without NAFLD at baseline (Supple-
mentary Table 1).
Cox regression analysis was used to
evaluate the independent association of
NAFLD with the risk of incident CKD (i.e.,
deﬁned as occurrence ofmacroalbuminu-
ria or eGFR,60 mL/min/1.73 m2 as esti-
mated by either the MDRD study
equation or the CKD-EPI equation) after
adjustment for potential confounders
(Table 2 and Supplementary Table 2).
For prediction of incident CKD, men and
women were combined and ﬁrst-order
interaction terms for sex-by-NAFLD inter-
actions on risk for CKD were examined.
Because the interactions were not statis-
tically signiﬁcant (P = 0.38), a sex-pooled
multivariate Cox regression analysis was
used. Three forced-entrymultivariate Cox
regression models were performed. The
ﬁrst regression model was adjusted for
age, sex, duration of diabetes, A1C, and
hypertension (i.e., blood pressure$140/
90 mmHg or drug treatment) (model 1),
the second model was additionally ad-
justed for baseline eGFR (i.e., a strong
risk factor for CKD) (model 2), and, ﬁnally,
the third model was adjusted for the
same covariates as model 2 after exclud-
ing those (n = 27) with microalbuminuria
at baseline (model 3). Covariates included
in the regression models were chosen as
potential confounding based on their bi-
ological plausibility or statistical associa-
tion with CKD in univariate analyses. We
also performed multivariate Cox regres-
sion analyses for each of the components
of the renal outcome, i.e., macroalbumi-
nuria and eGFR ,60 mL/min/1.73 m2,
separately.
Concordance Harrell c index, deﬁned
as the proportion of all usable patient
pairs in which predictors and outcomes
are concordant, was calculated for dif-
ferent Cox regression models. The c
index estimates the probability of
concordance between predicted and
observed CKD-free survival probability.
A value of 0.5 indicates no predictive
discrimination, and a value of 1.0
indicates a perfect separation of pa-
tients with different outcomes. By com-
paring c statistics with a nonparametric
approach, we evaluated the discrimina-
tory capability of the above-mentioned
regression models 1 and 2 with the use
of NAFLD as compared with the same
models without NAFLD (Table 3).
We also evaluated risk reclassiﬁcation
for regression models 1 and 2 with the
inclusion and exclusion of NAFLD, ac-
cording to the method developed by
Pencina et al. (24) for determining net
reclassiﬁcation improvement (NRI)
(Supplementary Tables 1 and 4).
A Kaplan-Meier analysis of incidence
curves for CKD during the follow-up was
also undertaken in patients with and
without NAFLD at baseline (Fig. 1). Dif-
ferences between groups were tested
by the log-rank test.
All analyses were performed using
statistical package SPSS 19 and STATA
10. Statistical signiﬁcance was assessed
at the two-tailed 0.05 threshold.
RESULTS
Table 1 shows the baseline characteris-
tics of the whole cohort of type 1
diabetic adults with preserved kidney
function and without macroalbuminuria.
At baseline, the mean eGFRMDRD was
92 6 23 mL/min/1.73 m2 (median 87.9
[IQR 74–104]), or eGFREPI was 98.6 6 19
mL/min/1.73 m2 (median 99.7 [84–112]).
Most patients (n = 234; 89.7%) had
normal albuminuria, whereas 27 pa-
tients (10.3%) had microalbuminuria.
NAFLD was present in 131 patients
(50.2%).
Table 1 also shows the baseline char-
acteristics of the cohort stratiﬁed by the
presence of incident CKDMDRD at follow-
up. At baseline, patients who developed
CKD at follow-up were older, more likely
to be female and obese, and had a longer
duration of diabetes than those who did
not. These patients also had higher values
of systolic blood pressure, A1C, triglycer-
ides, serum GGT, and urinary ACR and
lower values of eGFRMDRD and eGFREPI.
Moreover, there was a higher percentage
of patients with hypertension, metabolic
syndrome, microalbuminuria, and some
degree of diabetic retinopathy in patients
who developed CKD at follow-up com-
pared with those remaining free from
CKD. The proportion using antihyperten-
sive drugs (that always included the use
of ACE inhibitors or angiotensin receptor
blockers) was higher in those who
progressed to CKD. Notably, as shown in
Table 1, this patient group also had a
substantially higher frequency of NAFLD
on ultrasonography.
Baseline characteristics of the cohort
stratiﬁed by NAFLD status at baseline
are listed in Supplementary Table 1. As
expected, NAFLD patients were older
and more likely to be men compared
with their counterparts without NAFLD.
This group also had a higher prevalence
of the metabolic syndrome and its indi-
vidual components, a longer duration of
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diabetes, and higher serum liver en-
zymes (although the majority of NAFLD
patients had serum liver enzymes within
the normal range). Additionally, NAFLD
patients also had a higher frequency of
microalbuminuria and lower values of
eGFRMDRD and eGFREPI at baseline.
During follow-up (mean duration
5.26 1.7 years, range 2–10), 61 patients
developed CKD using the MDRD study
equation to estimate eGFR (i.e., ;4.5%
of participants progressed every year to
eGFR ,60 mL/min/1.73 m2 or macroal-
buminuria). Of these, 28 developed an
eGFRMDRD ,60 mL/min/1.73 m
2 with
abnormal albuminuria (micro- or macro-
albuminuria), 21 developed a reduced
eGFRMDRD with normal albuminuria
(but 9 of them had some degree of di-
abetic retinopathy at baseline), and 12
developed macroalbuminuria alone.
None of them developed kidney failure
requiring chronic dialysis.
At follow-up, patients who developed
CKD had a mean eGFRMDRD of 59 6 13
mL/min/1.73 m2, whereas those who did
not develop CKD had a mean eGFRMDRD
of 85 6 15 mL/min/1.73 m2. The annual
eGFRMDRD decline for the whole cohort
was 2.68 6 3.5 mL/min/1.73 m2 per
year. Interestingly, NAFLD patients had a
greater annual decline in eGFRMDRD than
those without NAFLD at baseline (3.286
3.8 vs. 2.10 6 3.0 mL/min/1.73 m2 per
year, P, 0.005). Similarly, the frequency
of a renal functional decline (arbitrarily
deﬁned as $25% loss of baseline
eGFRMDRD) was greater among those
with NAFLD than among those without
the disease (26 vs. 11%, P = 0.005).
Figure 1 shows a Kaplan-Meier analysis
of incidence curves for CKDMDRD during
the follow-up in patients with and with-
out NAFLD at baseline. The difference be-
tween the two groups was statistically
signiﬁcant (P < 0.001 by the log-rank
test). Almost identical results were found
when we used the CKD-EPI formula for
estimating eGFR (not shown).
Table 2 shows the effect of the adjust-
ment for known renal risk factors on the
relationship between NAFLD and inci-
dent CKD. In univariate regression anal-
ysis, NAFLD was signiﬁcantly associated
with an increased risk of incident CKD
(hazard ratio [HR] 2.85 [95% CI 1.59–
5.10], P, 0.001). Higher age, longer di-
abetes duration, higher A1C, higher se-
rum triglycerides, higher serum GGT
level, higher urinary ACR, hypertension,
and lower baseline eGFR were also sig-
niﬁcantly associated with incident CKD.
Interestingly, BMI was not signiﬁcantly
associated with CKD.
In multivariate regression analyses
(Table 2, models 1 and 2), NAFLD
maintained a signiﬁcant association
with the risk of incident CKD after
adjusting for age, sex, diabetes duration,
Table 1—Baseline clinical and biochemical characteristics of the cohort stratiﬁed by presence of incident CKD at follow-up
Variables Whole cohort (N = 261) No incident CKD (n = 200) Incident CKD (n = 61) P value*
Sex (male/female) 116/145 96/104 20/41 ,0.05
Age (years) 41 6 12 39 6 12 48 6 13 ,0.001
Diabetes duration (years) 18 (10–29) 16 (10–24) 28 (18–36) ,0.001
BMI (kg/m2) 24.5 6 4.6 24.2 6 4.3 25.9 6 5.4 ,0.05
Waist circumference (cm)§ 90.2 6 18 89.3 6 19 92.8 6 18 0.43
Current smokers (%) 24 26 18 0.18
Systolic blood pressure (mmHg) 128 6 17 126 6 16 136 6 20 ,0.001
Diastolic blood pressure (mmHg) 78 6 9 78 6 8 79 6 10 0.14
Fasting glucose (mmol/L) 10.6 6 4.2 10.6 6 3.9 10.4 6 4.7 0.71
A1C (%) 8.0 6 1.1 7.9 6 1.0 8.4 6 1.3 ,0.005
A1C (mmol/mol) 63.9 6 7 62.8 6 7 68.3 6 8 ,0.005
Triglycerides (mmol/L) 1.03 (0.73–1.43) 1.01 (0.73–1.37) 1.23 (0.84–1.97) ,0.01
HDL cholesterol (mmol/L) 1.41 6 0.4 1.38 6 0.3 1.46 6 0.5 0.20
LDL cholesterol (mmol/L) 2.64 6 0.8 2.61 6 0.7 2.76 6 0.9 0.19
eGFRMDRD (mL/min/1.73 m
2) 87.9 (74–104) 92.3 (84–110) 67.1 (62–83) ,0.001
eGFREPI (mL/min/1.73 m
2) 99.2 (84–112) 105.2 (94–116) 76.1 (69–90) ,0.001
Urinary ACR (mg/mmol) 1.0 (0.3–2.9) 1.2 (0.3–2.0) 3.1 (0.8–10.0) ,0.001
Microalbuminuria (%) 10 4 31 ,0.001
Diabetic retinopathy, any degree (%) 53 49 66 ,0.001
Metabolic syndrome (%) 35 31 48 ,0.01
Hypertension (%) 44 36 70 ,0.001
Antihypertensive drug users (%) 40 25 61 ,0.001
Insulin dose (units/day) 40 (28–55) 39 (27–54) 43 (30–62) 0.08
AST (units/L) 17 (13–24) 17 (12–23) 19 (13–25) 0.20
ALT (units/L) 19 (14–26) 19 (14–26) 20 (14–26) 0.66
GGT (units/L) 16 (11–29) 16 (11–25) 20 (12–39) ,0.05
NAFLD (%) 50 42 75 ,0.001
Cohort size: N = 261. Data are expressed as means 6 SD, medians (IQR), or proportions. Incident CKD was deﬁned as occurrence of
macroalbuminuria and/or eGFRMDRD ,60 mL/min/1.73 m
2 as estimated by the MDRD study equation. The metabolic syndrome was deﬁned by
a modiﬁed Adult Treatment Panel III deﬁnition. Hypertension was deﬁned as blood pressure$140/90 mmHg or antihypertensive treatment. ALT,
alanine aminotransferase; AST, aspartate aminotransferase. *P values for differences between those with and those without incident CKDMDRD at
follow-up that were assessed by the unpaired Student t test (for continuous variables) and by the x2 test (for categorical measures). §Measurement
of waist circumference was available in 102 patients only. All other parameters were available in all patients.
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hypertension, A1C, and baseline eGFR
(the latter being the strongest known
risk factor for CKD). In model 1, hyper-
tension and lower eGFR at baseline
were also independently associated
with incident CKD. As also shown in Ta-
ble 2, the signiﬁcant association be-
tween NAFLD and incident CKD was
only slightly weakened when we ex-
cluded those (n = 27) with microalbumi-
nuria at baseline (model 3) or when
we further adjusted the results of
model 2 for BMI and serum triglycerides
(adjusted HR 2.02 [95% CI 1.08–3.83],
P , 0.01).
In light of the well-known association
between alcohol consumption and liver
injury, we repeated all analyses de-
scribed above after excluding partici-
pants who drank minimally (n = 53).
Notably, the main results remained un-
changed (not shown).
Similar results were found for each of
the components of the renal outcome,
i.e., macroalbuminuria and eGFR ,60
mL/min/1.73 m2, separately. The pres-
ence of NAFLD signiﬁcantly predicted
subsequent development of either
eGFRMDRD ,60 mL/min/1.73 m
2 (ad-
justed HR 1.92 [95% CI 1.1–6.7], P ,
0.01) or macroalbuminuria (adjusted HR
5.41 [2.3–12.1],P, 0.001) after adjusting
for age, sex, diabetes duration, A1C, and
hypertension. However, given the rela-
tively small number of events, the results
of these latter multivariable regression
models should be interpreted with
some caution.
We undertook a sensitivity analysis,
by repeating the regression models
shown in Table 2, having estimated
eGFR according to the CKD-EPI equation
(that identiﬁed a lower number of inci-
dent CKD cases, n = 38). The results of
this supplementary analysis were very
similar to that obtained with eGFR cal-
culated fromMDRD study equation, and
the presence of NAFLD was again inde-
pendently associated with an increased
risk of CKD (Supplementary Table 2).
Table 3 shows the discriminatory ca-
pability of the regression models with
NAFLD as compared with the models
without NAFLD for predicting the risk
of incident CKD. Notably, all regression
models that included NAFLD resulted
in a better risk prediction for CKD
(i.e., a signiﬁcantly better c statistic)
than the models that did not include
NAFLD.
We also undertook net reclassiﬁcation
of risk based on regression model 1 and
model 2, according to the inclusion or
exclusion of NAFLD, for subjects in
whom CKDMDRD developed and for those
in whom CKDMDRD did not develop (Sup-
plementary Table 3A and B, models 1 and
2, respectively). We repeated these anal-
yses with CKDEPI as the outcome (Sup-
plementary Table 4A and B). In the
regression model 1 that adjusted for
age, sex, diabetes duration, A1C, and hy-
pertension, the inclusion of NAFLD reclas-
siﬁed, respectively, 10.5% of participants
when eGFR was estimated according to
the MDRD equation and 10.2% of partic-
ipants when eGFR was estimated accord-
ing to the CKD-EPI equation (P , 0.001
for both), primarily by reclassifying lower-
risk people into higher-risk categories. In
the regression model 2 that additionally
adjusted the results for baseline eGFR,
the inclusion of NAFLD appropriately re-
classiﬁed smaller proportions of partici-
pants (NRI = 4.6% and P = 0.073 for
regression models with CKDMDRD as out-
come; NRI = 2.5% and P = 0.01 for regres-
sion models with CKDEPI as outcome).
CONCLUSIONS
Our novel ﬁndings indicate that NAFLD is
strongly associated with an increased in-
cidence of CKD during a mean follow-up
Table 2—Univariate and multivariate Cox regression analyses showing associations of NAFLD and other factors with risk of
incident CKD among type 1 diabetic adults
Univariate
analysis P value
Multivariate model
1 P value
Multivariate model
2 P value
Multivariate model
3 P value
NAFLD (yes vs. no) 2.85 (1.59–5.10) ,0.001 2.26 (1.22–4.20) ,0.01 2.03 (1.10–3.77) ,0.01 1.85 (1.03–3.27) ,0.05
Sex (female vs. male) 1.43 (0.84–2.43) 0.19 1.54 (0.90–2.68) 0.14 0.75 (0.40–1.41) 0.37 0.93 (0.42–2.18) 0.86
Age (years) 1.03 (1.01–1.04) ,0.001 1.01 (0.98–1.04) 0.37 1.01 (0.97–1.03) 0.96 1.01 (0.97–1.05) 0.65
Diabetes duration
(years) 1.02 (1.01–1.04) ,0.001 1.01 (0.98–1.03) 0.74 1.01 (0.97–1.02) 0.71 1.0 (0.97–1.03) 0.94
Hypertension
(yes vs. no) 2.32 (1.40–4.38) ,0.001 1.96 (1.06–3.61) ,0.05 1.90 (1.02–3.39) ,0.05 1.75 (0.99–2.97) 0.06
A1C (%) 1.17 (1.02–1.37) ,0.05 1.11 (0.93–1.34) 0.26 1.09 (0.92–1.31) 0.32 1.15 (0.92–1.41) 0.29
eGFRMDRD
(mL/min/1.73 m2) 0.94 (0.91–0.96) ,0.001 0.95 (0.92–0.97) ,0.001 0.94 (0.91–0.97) ,0.001
Urinary ACR
(mg/mmol) 1.08 (1.05–1.10) ,0.001
BMI (kg/m2) 1.03 (0.99–1.08) 0.09
Smokers (yes vs. no) 1.22 (0.63–2.38) 0.56
Triglycerides (mmol/L) 1.01 (1.01–1.03) ,0.01
HDL cholesterol
(mmol/L) 1.0 (0.98–1.01) 0.76
LDL cholesterol
(mmol/L) 1.0 (0.99–1.01) 0.32
Cohort size: N = 261. Data are presented as HRs (695% CIs) by Cox regression analysis. Incident CKD was deﬁned as occurrence of macroalbuminuria
and/or eGFRMDRD ,60 mL/min/1.73 m
2 as estimated by the MDRD study equation. CKDMDRD identiﬁed 61 subjects who developed CKD during
follow-up. Multivariable regression model 1, adjustment for age, sex, duration of diabetes, A1C, and hypertension (blood pressure$140/90 mmHg
or drug treatment); multivariable regression model 2, adjustment for age, sex, duration of diabetes, A1C, hypertension, and baseline eGFRMDRD;
multivariable regression model 3, adjustment for the same covariates as model 2 after excluding those (n = 27) with microalbuminuria at baseline.
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of 5 years and that measurement of
NAFLD improves risk prediction for CKD,
independently of traditional risk factors
(age, sex, diabetes duration, A1C, hyper-
tension, baseline eGFR, andmicroalbumi-
nuria [i.e., the last two factors being the
strongest known risk factors for CKD]), in
type 1 diabetic adults. Additionally, al-
though NAFLD was strongly associated
with obesity, obesity (or increased BMI)
did not explain the association between
NAFLD and CKD.
Since it remains uncertain which of the
two eGFR equations is superior in patients
with type 1 diabetes, we used both the
MDRD and CKD-EPI equations to estimate
eGFR. As shown in Table 3, it is worth
noting that the two eGFR equations
identiﬁed a different number of incident
CKD cases (n = 61 using the MDRD equa-
tion and n = 38 using the CKD-EPI equa-
tion). However, with both the MDRD and
CKD-EPI equations, the discriminatory ca-
pability (c statistic) and the NRI of the re-
gression models that included NAFLD
were substantially comparable (for pre-
dicting incident CKD). Since there were
relatively few incident CKD events in our
cohort, we did not undertake formal sta-
tistical analyses to compare the NRI data
obtained with both eGFR equations. We
suggest that further follow-up studies on
larger cohorts of patients with type 1 di-
abetes are nowneeded to improve under-
standing of this issue.
The annual cumulative incidence rate
of CKD in our cohort of patients (i.e.,
;4.5% per year) was essentially
comparable to that previously described
in other European populations with type
1 diabetes and similar baseline charac-
teristics (;2.5–9% of patients who pro-
gressed every year to CKD) (25,26). In
line with previously published informa-
tion (25–28), we also found that hyper-
tension, microalbuminuria, and lower
eGFR at baseline were strong predictors
of incident CKD in type 1 diabetic
patients.
Another interesting ﬁnding of our
study that corroborates our previously
published observations (15,16) is that
the frequency of NAFLD on ultrasonog-
raphy was high in type 1 diabetic adults
(i.e., ;50% of our patients had hepatic
steatosis), and that the majority of pa-
tients with NAFLD had serum liver en-
zymes within the “normal” reference
ranges. This further suggests that serum
liver enzyme levels are insensitive
markers for the detection of NAFLD,
and that the “normal” reference values
for serum liver enzymes currently used
to exclude NAFLD need to be revised
(1,2,8).
There is a pressing and unmet need to
determine whether NAFLD is associated
with a higher risk of CKD in people with
type 1 diabetes. It has only recently
been recognized that NAFLD represents
an important burden of disease for
type 2 diabetic patients (11,17,18), but
the magnitude of the problem of NAFLD
and its association with risk of CKD in
type 1 diabetes is presently poorly rec-
ognized. Although there is clear evi-
dence that NAFLD is closely associated
with a higher prevalence of CKD both in
those without diabetes (11) and in those
with type 1 and type 2 diabetes (15–17),
only four prospective studies have ex-
amined the association between NAFLD
and risk of incident CKD (18,29–31), and
only one of these studies was published
in patients with type 2 diabetes (18). In-
deed, in this prospective study, involv-
ing 1,760 type 2 diabetic individuals
with preserved kidney function and
not macroalbuminuria at baseline, we
found that ultrasound-diagnosedNAFLD
was associated with an increased inci-
dence of CKD, independently of several
established cardio-renal risk factors
(18). Similarly, Chang et al. (29), follow-
ing an occupational cohort of 8,329
nondiabetic men with normal kidney
function and no proteinuria at baseline
for a mean period of;3.5 years, showed
Table 3—Discriminatory capability and NRI* of the regression models with NAFLD
as compared with the models without NAFLD for predicting the risk of developing
incident CKD in adult patients with type 1 diabetes
Prediction model
Without NAFLD With NAFLD
Regression models with CKDMDRD as outcome
Regression model 1
Discriminatory capability
c statistic 0.66 0.70
95% CI 0.58–0.74 0.62–0.78
P value for difference ,0.001
NRI (%) 10.5
P value ,0.001
Regression model 2
Discriminatory capability
c statistic 0.76 0.79
95% CI 0.71–0.84 0.73–0.86
P value for difference 0.002
NRI (%) 4.6
P value 0.073
Regression models with CKDEPI as outcome
Regression model 1
Discriminatory capability
c statistic 0.73 0.81
95% CI 0.65–0.81 0.75–0.87
P value for difference ,0.001
NRI (%) 10.2
P value ,0.005
Regression model 2
Discriminatory capability
c statistic 0.81 0.87
95% CI 0.75–0.88 0.82–0.92
P value for difference 0.002
NRI (%) 2.5
P value 0.01
Incident CKD was deﬁned as occurrence of macroalbuminuria and/or eGFR,60 mL/min/1.73 m2
(using either the MDRD study equation or the CKD-EPI equation). Multivariable regression
model 1, adjustment for age, sex, diabetes duration, A1C, and hypertension; multivariable
regression model 2, adjustment for age, sex, diabetes duration, A1C, hypertension, and
baseline eGFR. *Complete data on net reclassiﬁcation of risk according to the inclusion or
exclusion of NAFLD for subjects in whom CKD developed and for those in whom CKD did not
develop are reported in Supplementary Table 3 (regression models with CKDMDRD as outcome)
and Supplementary Table 4 (regression models with CKDEPI as outcome).
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that ultrasound-diagnosedNAFLDwas as-
sociated with an increased incidence of
CKD, even after adjusting for several po-
tential confounders, including insulin re-
sistance and C-reactive protein. Two
other large community-based cohort
studies, using elevated serum GGT levels
as proxy markers for NAFLD, have also
shown that NAFLDwas independently as-
sociated with an increased incidence of
kidney disease (30,31).
The underlying mechanisms responsi-
ble for the observed association be-
tween NAFLD and CKD are not well
understood. Speculatively, the most
plausible explanation for our ﬁndings
is that the association between NAFLD
and risk of incident CKD is simply a con-
sequence of shared cardio-renal risk
factors and comorbidities. However,
since the association between NAFLD
and CKD was independent of shared
risk factors, and inclusion of NAFLD
improved the discriminatory capability
of regression models for predicting
CKD, our ﬁndings suggest that NAFLD
is not only a marker of CKD but may
also be partly involved in its pathogen-
esis. Experimental evidence suggests
that NAFLD itself releases a variety of
proinﬂammatory, procoagulant, pro-
oxidant, and proﬁbrogenic mediators
that may play important roles in the
development and progression of CKD
(11,32–35).
The possible clinical implication for
these ﬁndings is that type 1 diabetic pa-
tients with NAFLD may beneﬁt from
more intensive surveillance or early
treatment interventions to decrease
the risk for CKD. Currently, there is no
approved treatment for NAFLD. How-
ever, NAFLD and CKD share numerous
cardiometabolic risk factors, and treat-
ment strategies for NAFLD and CKD
should be similar and aimed primarily
at modifying the associated cardiometa-
bolic risk factors.
The major limitations of this study are
its retrospective, longitudinal design
(which does not allow us to draw any
ﬁrm conclusion about causality) and a
possible selection bias of excluding the
patients who had missing liver ultraso-
nographic data at baseline. In addition,
we used an eGFR instead of a directly
measured GFR to deﬁne kidney func-
tion. However, current GFR estimates
facilitate the evaluation and manage-
ment of CKD, and many organizations
recommend the use of prediction equa-
tions for the evaluation of kidney func-
tion in clinical practice (14,21,36).
Another possible limitation of our study
was that the diagnosis of NAFLD was
based on ultrasonography (that is rela-
tively insensitive to the presence of
smaller amounts of hepatic steatosis,
i.e., ,30% liver fat inﬁltration) and the
exclusion of other secondary causes of
chronic liver disease, but was not
conﬁrmed by liver biopsy, which would
be unethical to perform in our patients
who had normal or only slightly elevated
serum liver enzyme levels. Thus, al-
though some nondifferential misclassiﬁ-
cation of NAFLD on the basis of
ultrasonography is likely (some of the
diabetic control patients could have un-
derlying NAFLD despite normal serum
liver enzymes and negative ultrasonog-
raphy examination), this limitation
would serve to attenuate themagnitude
of our effect measures toward null;
thus, our results can probably be consid-
ered to be conservative estimates of the
relationship between NAFLD and risk of
CKD. It is also important to underline
that self-reporting of alcohol consump-
tion may be unreliable and often under-
estimates the true risk. However, the
main results of our study remained un-
changed when participants who were
light-to-moderate drinkers were ex-
cluded from analysis. Finally, whether
these observations can also be extended
to non-Caucasian ethnic groups remains
to be determined.
Notwithstanding these limitations, our
study has several strengths, such as the
relatively large sample size, the long du-
ration of follow-up, the completeness of
the dataset, and the ability to adjust for
multiple established cardio-renal risk
factors and potential confounders. In ad-
dition, our patients were free from diag-
nosed CVD and cirrhosis; the evaluation
Figure 1—Incidence curves for CKDMDRD during the follow-up in type 1 diabetic patients with (dotted line) and without (solid line) NAFLD on
ultrasonography at baseline.
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of patients with such complications
would almost certainly have confounded
interpretation of the data.
In conclusion, this is the ﬁrst study to
demonstrate that NAFLD is strongly asso-
ciated with an increased incidence of CKD,
and thatmeasurementofNAFLD improves
the risk prediction of CKD, independently
of traditional cardio-renal risk factors, in
type 1 diabetic adults. Further large,
long-term prospective studies are needed
to conﬁrm our results (before suggesting a
routine liver ultrasound examination in all
patients with type 1 diabetes to better
predict the future development of CKD)
and to determine whether improvement
inNAFLD (or future treatments for NAFLD)
will ultimately delay or prevent the devel-
opment and progression of CKD in pa-
tients with type 1 diabetes.
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